Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study

Research output: Contribution to journal › Article › peer-review

Access to Document

@article{4badf4baf11f42ddac93a61ab6194d43,

title = "Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study",

author = "Grace Wang",

note = "Clinical Cancer Research (2021) 27(11):3061-3068.",

year = "2021",

month = jun,

day = "1",

language = "American English",

volume = "27",

journal = "Clinical Cancer Research",

}

TY - JOUR

T1 - Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study

AU - Wang, Grace

N1 - Clinical Cancer Research (2021) 27(11):3061-3068.

PY - 2021/6/1

Y1 - 2021/6/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3843

M3 - Article

VL - 27

JO - Clinical Cancer Research

JF - Clinical Cancer Research

ER -